BAYOU: A phase II, randomized, multicenter, double-blind, study of durvalumab (D) in combination with olaparib (O) for the first-line treatment of platinum-ineligible patients with unresectable, stage IV urothelial carcinoma (UC) Meeting Abstract
| Authors: | Rosenberg, J. E.; Park, S. H.; Dao, T. V.; Castellano, D. E.; Li, J. R.; Mukherjee, S.; Howells, K.; Dry, H.; Lanasa, M. C.; Stewart, R.; Bajorin, D. F. |
| Abstract Title: | BAYOU: A phase II, randomized, multicenter, double-blind, study of durvalumab (D) in combination with olaparib (O) for the first-line treatment of platinum-ineligible patients with unresectable, stage IV urothelial carcinoma (UC) |
| Meeting Title: | 2022 ASCO Genitourinary Cancers Symposium |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 40 |
| Issue: | 6 Suppl. |
| Meeting Dates: | 2022 Feb 17-19 |
| Meeting Location: | San Francisco, CA |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2022-02-20 |
| Language: | English |
| ACCESSION: | WOS:000771008900443 |
| DOI: | 10.1200/JCO.2022.40.6_suppl.437 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 437 -- Meeting was conducted online as well as in person -- Source: Wos |
Altmetric
Citation Impact
BMJ Impact Analytics
